References

Cucuzzella M, Riley K Isaacs. Adapting medication for type 2 diabetes in the context of therapeutic carbohydrate restriction. Nutrition Network (eds). Ketogenic: the science of therapeutic carbohydrate restriction in human health. 2023;

Gallagher EJ, LeRoith D Hyperinsulinaemia in cancer. Nat Rev Cancer.. 2020; 20:(11)629-644 https://doi.org/10.1038/s41568-020-0295-5

Giovannucci E The critical need for guidance in managing glycaemic control in patients with cancer. Diabetic Med. 2022; 39 https://doi.org/10.1111/dme.14624

Johnson JD On the causal relationships between hyperinsulinaemia, insulin resistance, obesity and dysglycaemia in type 2 diabetes. Diabetologia.. 2021; 64:2138-2146

Noakes TD The adoption and evolution of dietary guidelines. Nutrition Network (eds). Ketogenic: the science of therapeutic carbohydrate restriction in human health. 2023;

Thomas DD, Corkey BE, Istfan NW, Apovian CM Hyperinsulinemia: An Early Indicator of Metabolic Dysfunction. J Endocr Soc.. 2019; 3:(9)1727-1747 https://doi.org/10.1210/js.2019-00065

Zhang AMY, Magrill J, de Winter TJJ Endogenous Hyperinsulinemia Contributes to Pancreatic Cancer Development. Cell Metab.. 2019; 30:403-404 https://doi.org/10.1016/j.cmet.2019.07.003

Zhang AMY, Xia YH, Lin JSH Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation. Cell Metab. 2023; 35:(12)2119-2135 https://doi.org/10.1016/j.cmet.2023.10.003

Hyperinsulinaemia

02 January 2024
Volume 6 · Issue 1

Abstract

George Winter discusses the need to evaluate the respective roles of diet, lifestyle, and pharmaceuticals in relation to improving glycaemic and insulin control in type 2 diabetes

The idea of type 2 diabetes (T2D) being a progressive illness is almost redundant, with increasing evidence even confirming how T2D remission is possible. For example, Cucuzzella et al (2023: 146) note that therapeutic carbohydrate restriction is an effective option in T2D management, improving the condition, reducing medication burden and achieving weight loss.

Accordingly, there has been a move away from medical practice that concentrates ‘almost exclusively on prescribing and intensifying medical therapy as chronic disease progresses’ and towards ‘safely de-prescribing medications’ (Cucuzzella et al, 2023).

As Johnson (2021) observes, T2D ‘is much more reversible than was once thought’ and since ‘[m]ost drugs are designed to combat hyperglycaemia, counteract the deficiency in glucose-stimulated insulin secretion, and increase insulin sensitivity in the context of frank diabetes’, it is arguable that substantial pathology has occurred before deranged glucose concentrations are detected, and that some drug-related approaches ‘may be double-edged swords.’

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month